BIOMAT Database Logo BIOMAT Database Logo

Clinical and biochemical studies in mucopolysaccharidosis type II carriers. 2009

I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Department of Genetics, UFRGS, Porto Alegre, Brazil. ida.ez@terra.com.br.

The aim of the study was to characterize clinically and biochemically mucopolysaccharidosis type II (MPS II) heterozygotes. Fifty-two women at risk to be a carrier, with a mean age of 34.1 years (range 16-57 years), were evaluated through pedigree analysis, medical history, physical examination, measurement of iduronate sulfatase (IDS) activities in plasma and in leukocytes, quantification of glycosaminoglycans (GAGs) in urine, and analysis of the IDS gene. Eligibility criteria for the study also included being 16 years of age or older and being enrolled in a genetic counselling programme. The pedigree and DNA analyses allowed the identification of 40/52 carriers and 12/52 non-carriers. All women evaluated were clinically healthy, and their levels of urinary GAGs were within normal limits. Median plasma and leukocyte IDS activities found among carriers were significantly lower than the values found for non-carriers; there was, however, an overlap between carriers' and non-carriers' values. Our data suggests that MPS II carriers show lower plasma and leukocyte IDS activities but that this reduction is generally associated neither with changes in levels of urinary GAGs nor with the occurrence of clinical manifestations.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D010808 Physical Examination Systematic and thorough inspection of the patient for physical signs of disease or abnormality. Physical Exam,Examination, Physical,Physical Examinations and Diagnoses,Exam, Physical,Examinations, Physical,Exams, Physical,Physical Examinations,Physical Exams
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005190 Family A social group consisting of parents or parent substitutes and children. Family Life Cycles,Family Members,Family Life Cycle,Family Research,Filiation,Kinship Networks,Relatives,Families,Family Member,Kinship Network,Life Cycle, Family,Life Cycles, Family,Network, Kinship,Networks, Kinship,Research, Family
D005192 Family Health The health status of the family as a unit including the impact of the health of one member of the family on the family as a unit and on individual family members; also, the impact of family organization or disorganization on the health status of its members. Health, Family
D005260 Female Females
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006025 Glycosaminoglycans Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine (see ACETYLGLUCOSAMINE) or N-acetylgalactosamine (see ACETYLGALACTOSAMINE). Glycosaminoglycan,Mucopolysaccharides
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes

Related Publications

I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Mucopolysaccharidosis type I: clinical and biochemical study.
January 2000, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study.
June 2013, Orphanet journal of rare diseases,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers.
July 2006, Clinica chimica acta; international journal of clinical chemistry,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
[Mucopolysaccharidosis type VII. Clinical, radiological and biochemical studies in a neonatal case (author's transl)].
October 1981, Archives francaises de pediatrie,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
[Clinical aspects of mucopolysaccharidosis type II].
February 2007, Revista de neurologia,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome.
January 2017, Orphanet journal of rare diseases,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
[The heparitinsulfate mucopolysaccharidosis (Sanfilippo). Clinical, biochemical, genetic and morphological studies].
May 1967, Klinische Wochenschrift,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Morphological and biochemical studies of a case of mucopolysaccharidosis II (Hunter's syndrome).
January 1976, Acta pathologica japonica,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
June 2011, Current pharmaceutical biotechnology,
I V D Schwartz, and L L C Pinto, and G Breda, and L Lima, and M G Ribeiro, and J G Mota, and A X Acosta, and P Correia, and D D G Horovitz, and C G G Porciuncula, and E Lipinski-Figueiredo, and A C Fett-Conte, and R P Oliveira Sobrinho, and D Y J Norato, and A C Paula, and C A Kim, and A R Duarte, and R Boy, and S Leistner-Segal, and M G Burin, and R Giugliani
Clinical utility gene card for: mucopolysaccharidosis type II.
January 2012, European journal of human genetics : EJHG,
Copied contents to your clipboard!